ValiRx Regulatory News (VAL)

ValiRx Plc

("ValiRx" or "the Company")

ValiSeek Clinical Development Update

Recruitment closes

London, UK., 15 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the clinical development of ValiSeek Limited ("ValiSeek"), the joint venture ("JV") between ValiRx and Tangent Reprofiling Limited.

ValiSeek was formed to progress the novel cancer treatment drug, VAL401, into clinical trials for the treatment of lung cancer and other oncology indications. Since its last clinical update on 8 March 2017, ValiSeek is pleased to report continued progress of the trial of VAL401 in the treatment of non-small cell lung cancer.

The VAL401 trial treating patients with non-small cell lung cancer has completed the recruitment phase. ValiSeek has decided there was no requirement to enrol further patients and will continue to measure the outcomes of those patients currently on trial, while commencing analysis of the results to date.

A total of 8 patients have been enrolled into the trial for treatment and the data collected from these participants, will be compared to data being collected in case-matched untreated patients from the same clinics, providing a minimum of a 20 subject cohort for data comparison.

As announced previously, the protocol allows a preliminary datalock after collection of all "Day 15" pharmacokinetic samples. Now that recruitment is complete, the data checking and database formation for these figures is underway, after which they will be passed to the analysis team. This process of data processing and analysis is expected to be returned in Q3.

The protocol allows dosing of patients for up to six months, so the trial remains on track to be completed by the year end, following which further data processing and analysis will be performed.

These details will be discussed by Dr Suzanne Dilly, CEO of ValiSeek at the BIO International Convention in San Diego next week (June 19 - 22). (For more information on the BIO International Convention, please see below) 

Dr Suzy Dilly, CEO of ValiSeek, commented: "We are delighted to have been able to close on schedule, due to our confidence in the results that we are generating. Completion of recruitment and securing the untreated patient comparison data has been a big step forwards for our trial. The pharmacokinetic and safety data seen to date appears comparable to that expected and we are excited by and anticipate keenly the formal analysis of the data, so as to interpret and understand our observations more fully."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

Notes for Editors

About the BIO International Convention

The BIO International Convention in San Diego (June 19-22, 2017) is the largest global event for the biotechnology industry. The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders and unparalleled networking opportunities with over 16,000 attendees from 76 countries.

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the novel cancer treatment drug, VAL401, through its remaining pre-clinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.